This federal contract award, SPE2D020D0009|SPE2D325F6837, was issued by the Defense Logistics Agency (DLA) Medical Supply Chain to Fresenius Kabi, LLC, a foreign-owned, for-profit pharmaceutical company based in Lake Zurich, Illinois. The contract is for the delivery of Lidocaine Hydrochloride Injection USP 25, a critical care pharmaceutical product, with an ultimate completion date of February 27, 2025. The contract is a firm fixed-price delivery order with a ceiling value of $1,947.33. The contract has no set-aside designation and is not associated with a larger contract vehicle. Fresenius Kabi, LLC is the prime contractor and has no major subcontractors listed. This contract is part of the company's broader role as a key vendor in the federal medical supply chain, providing a wide range of injectable pharmaceuticals and medical solutions to various federal healthcare systems, including the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, and Indian Health Service.
Generated 6/1/25, 3:28 AM